Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd., a leading global healthcare company headquartered in Japan, has established itself as a key player in the pharmaceutical and nutraceutical industries. Founded in 1964, Otsuka has made significant strides in developing innovative products that address unmet medical needs, particularly in areas such as mental health, oncology, and cardiovascular health. With a strong presence in regions including North America, Europe, and Asia, Otsuka is renowned for its unique offerings, such as the antipsychotic medication Abilify and the hydration solution Pocari Sweat. The company’s commitment to research and development has led to numerous breakthroughs, solidifying its market position and earning recognition for its contributions to global health. Otsuka continues to focus on advancing science and improving patient outcomes through its diverse portfolio of pharmaceuticals and nutraceuticals.
DitchCarbon Score
How does Otsuka Pharmaceutical Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Otsuka Pharmaceutical Co., Ltd.'s score of 60 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Otsuka Pharmaceutical Co., Ltd., headquartered in Japan, has set ambitious climate commitments aimed at significantly reducing its greenhouse gas (GHG) emissions. The company has pledged to reduce absolute Scope 1 and Scope 2 GHG emissions by 30% by 2030, using 2017 as the baseline year. Additionally, Otsuka aims to cut its absolute Scope 3 emissions by 20% within the same timeframe. These targets are aligned with the Science Based Targets initiative (SBTi) and reflect Otsuka's commitment to contributing to global efforts to limit temperature rise to 2°C. The reduction targets encompass emissions from the company's direct operations (Scope 1), indirect emissions from purchased energy (Scope 2), and other indirect emissions across its value chain (Scope 3). As of now, there is no specific emissions data available for Otsuka Pharmaceutical Co., Ltd. However, the company's proactive stance on climate action is evident through its established reduction targets, which are cascaded from its parent organization, Otsuka Holdings Co., Ltd. This corporate family relationship underscores Otsuka's commitment to sustainability within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2011 | 2012 | 2016 | 2017 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 285,728,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 116,816,000 | 000,000,000 | 000,000,000 | - | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 402,544,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Otsuka Pharmaceutical Co., Ltd. is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
